CanBas Co.,Ltd. (4575) Stock Price

Canvas is a biotech venture specializing in cancer drug development. Using its proprietary drug discovery platform (discovery engine), the company conducts integrated research from basic science through preclinical and early-to-late stage clinical development. Operating as a single pharmaceutical business segment, Canvas aims to create and commercialize its own drug candidates.

The company's primary "customers" are not end patients at this stage. Revenue currently depends on licensing agreements, collaborative research fees, and funding from investors and capital markets. As development progresses, revenue is expected to come from milestone payments and royalties through licensing deals with pharmaceutical companies, as well as future product sales. Canvas is strengthening its financial foundation by strategically choosing between in-house development and strategic partnerships.

Canvas's key pipeline includes CBP501, which activates immunity to attack "cold tumors," currently preparing for the next phase after completing Phase 2 trials in pancreatic cancer. CBS9106, previously licensed to external partners, has had its rights returned and is under review for revised development strategy. The company is also exploring and optimizing preclinical candidates including CBT005, CBP-A08, and IDO/TDO inhibitors. Canvas advances development through partnerships with major CROs, universities, and scientific advisors, selecting either in-house continuation or collaboration for each pipeline program.

The company aims to grow as a "drug discovery company" that creates both technologies and products in-house by conducting integrated research from basic science through clinical development, centered on its proprietary drug discovery engine. It positions CBP501 as its first marketed product and has set its early approval and market launch as the top priority for the medium to long term. The company has completed Phase 2 clinical trials for pancreatic cancer and is preparing for the next phase. It holds cash and deposits of 2,827,879 thousand yen to sustain operations, but places strong emphasis on financial planning since external revenue will be limited until market launch.

Priority investment areas are clinical development of CBP501 and enhancement of its drug discovery engine. Differentiation is based on its proprietary drug discovery methodology and feedback from clinical insights. Specifically, the company has obtained evidence of enhanced efficacy by combining CBP501 with cisplatin and antibodies that activate immunity, and plans to advance to the next phase after completing Phase 2 trials with the three-drug combination. Simultaneously, it has acquired candidates from its proprietary screening method that leverages differences in cell division processes, as well as candidates targeting cancer immunotherapy and cancer stem cells (CBT005, CBP-A08, etc.), which serve as sources of competitive advantage.

The company pursues new market development and business expansion through strategic partnerships and intellectual property transfers with pharmaceutical companies. Beyond direct patient sales, it plans to generate revenue from joint research fees, technology licensing income, milestone payments from license agreements, and future sales revenue. It selects partnership candidates for each project based on funding needs. The company also conducts capital raises through new share issuance as needed and collaborates with CROs, universities, and external experts to accelerate development and manage risk.

Regarding technological innovation, the company commits to further improving its existing drug discovery engine and continuing to create and optimize new candidates. It strengthens mechanisms to feed clinical trial data back into drug discovery and pursues next-generation pipeline development by advancing specialized exploration in immunotherapy and stem cells alongside conventional screening methods. Through such research investment and external evaluation, the company aims to diversify development risk and ensure long-term business sustainability.